Purdue Pharma L.P. has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for an immediate-release oxycodone HCl formulation designed with the intent to deter intranasal and intravenous abuse of the medication.

The proposed indication for the investigational drug is for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.